AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02431936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
Study NCT02431936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill made to look identical to Prazosin intervention.
Study NCT04948775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises
Description: A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
Study NCT01100515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normobaric oxygen therapy
Description: oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
Study NCT01100515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
Study NCT03621332 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Online/paper questionnaires
Study NCT01422915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colestipol
Description: 2 grams morning and bedtime for 90 days.
Study NCT01071538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
Study NCT00784381 — intervention group
Intervention type: DEVICE
Intervention: computer-assisted counselling about target drugs
Description: implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
Study NCT04474795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff -Educational training
Description: Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
Study NCT04030923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study NCT01670487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant
Description: Topical stream of 4 to 10 seconds duration to skin
Study NCT01670487 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Topical intervention of sterile water stream 4 to 10 seconds to skin.
Study NCT00804076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP2
Description: Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
Study NCT04030923 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
Study NCT03455491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 100 mg
Description: once daily during 3 days.
Study NCT03455491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 200 mg
Description: once daily during 3 days.
Study NCT03455491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily during 3 days.
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Stem Cell Mobilization
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Stem Cell Mobilization
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Transplantation Conditioning
Study NCT03630211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: Transplantation Conditioning
Study NCT02331433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: APN1125 orally at ascending doses
Study NCT02331433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01650961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.075 mg IV as bolus before induction of general anesthesia
Study NCT01650961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline as bolus before induction of general anesthesia
Study NCT02505503 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unloading shoes
Description: The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
Study NCT02505503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloading shoes
Description: The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
Study NCT02505503 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Unadapted control shoe
Description: During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
Study NCT02505503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unadapted control shoe
Description: During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
Study NCT03073980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen for pain control during procedure
Study NCT03073980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: PO Acetaminophen for pain control during procedure
Study NCT03073980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IV Acetaminophen
Description: Placebo IV Acetaminophen
Study NCT03073980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Acetaminophen
Description: Placebo IV Acetaminophen
Study NCT03073980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PO Acetaminophen
Description: Placebo PO Acetaminophen
Study NCT03073980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO Acetaminophen
Description: Placebo PO Acetaminophen
Study NCT03046485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management program 'Living with Vision Loss'
Description: group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
Study NCT04001621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with capecitabine
Description: pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
Study NCT03710109 — intervention group
Intervention type: OTHER
Intervention: EEG
Description: non-invasive, non-interventional sensor
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Digital rectal exam and / or anal cytology (day 1 and after 36 months)
Description: For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy
Description: For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)
Description: For Cervix Screening in sexually active woman (day 1 and after 36 months)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semestral cervical cytology and cervical sample for HPV detection
Description: For Cervix Screening in sexually active woman (semestral)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Appointment for mammography (day 1 and after 36 months)
Description: For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual appointment for mammography
Description: For Breast Screening in woman between 45-70 years old (annual)
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Semestral appointment for liver ultrasound
Description: For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~* Asian male> 40 years old~* Asian woman> 50 years old~* African man or woman~* HCC family history
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semestral appointment for liver ultrasound
Description: Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination
Description: Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal occult blood test (day 1 and after 36 months)
Description: For Colon Screening:~Age between 50-70 years old
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual fecal occult blood test
Description: For Colon Screening:~Age older than 40 years
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Digital rectal exam and PSA determination (day 1 and after 36 months)
Description: For Prostate Screening:~Man older than 50 years
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual digital rectal exam and PSA determination
Description: For Prostate Screening:~Man older than 50 years
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual appointment for low dose computed tomography for lung screening
Description: For Lung Screening: should accomplish~ALL the following criteria:~* Age > 40 years~* Active smoker or former smoker\<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~* No contraindications for thoracic surgery~* No lung infection in the last 2 months
Study NCT04735445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual general inspection for skin lesions suggestive of malignancy
Description: For Skin Screening:~Woman ≥18 years Man ≥40 years
Study NCT00577642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid
Description: 4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
Study NCT00185952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
Study NCT00185952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
Study NCT01840579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Description: Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
Study NCT01840579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Description: Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
Study NCT01840579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m^2
Description: Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg
Description: Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
Study NCT01840579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (pegfilgrastim) 3.6 mg
Description: Administered as a subcutaneous injection on Day 4 of Cycle 1
Study NCT03860675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of walking-related fatigability
Description: participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
Study NCT03860675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of walking-related fatigability
Description: participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
Study NCT05693636 — intervention group
Intervention type: PROCEDURE
Intervention: Total wrist arthroplasty
Description: Two different surgical interventions for treatment of end-stage arthritis are compared
Study NCT01352832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive DVD
Description: An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor.
Study NCT01352832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT03949933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton and carbon ion radiotherapy
Description: proton and carbon ion radiotherapy
Study NCT00472264 — intervention group
Intervention type: PROCEDURE
Intervention: PET imaging
Description: Medical imaging assessment
Study NCT04111640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CoRe software
Description: Computer-supported cognitive training (CT)
Study NCT04111640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Paper and pencil cognitive training (paper-and-pencil CoRe version)
Study NCT01744665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
Study NCT03990064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musicotherapy
Description: receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
Study NCT02799823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
Study NCT02281032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interRAI PC
Description: PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results